Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 3/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25762020 | 0.86 | CYP19A1 (0.43) | ALDH1A1CYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL2076101 | 0.81 | S1PR3 (0.41) | ALDH1A1CYP1A2CYP2C9CYP2C19CYP19A1 | |
| SCHEMBL25077473 | 0.78 | CYP19A1 (0.36) | ALDH1A1CYP1A2CYP2C9CYP2C19CYP19A1 | |
| SCHEMBL25077137 | 0.78 | P2RX3 (0.42) | CYP1A2CYP2C9CYP2C19CYP19A1KDM4E | |
| SCHEMBL25024965 | 0.78 | ALDH1A1 (0.48) | ALDH1A1CYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL31053865 | 0.78 | ALDH1A1 (0.48) | ALDH1A1CYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL12391448 | 0.76 | ALDH1A1 (0.52) | ALDH1A1CYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL16335028 | 0.75 | ALDH1A1 (0.60) | ALDH1A1CYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL12391530 | 0.75 | ALDH1A1 (0.53) | ALDH1A1CYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL25077412 | 0.74 | CYP19A1 (0.47) | CYP19A1CYP11B1CYP11B2S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10233177-B2 | TRPV1 vanilloid receptor antagonists with a bicyclic portion | SERENTRIX, LLC | 2019-03-19 | — | — | US | disclosed |
| EP-2552888-B1 | TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION | SERENTRIX LLC (US) | 2018-09-26 | — | — | EP | disclosed |
| US-20170152252-A1 | TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion | SERENTRIX, LLC | 2017-06-01 | — | — | US | disclosed |
| US-20160289199-A1 | TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion | SERENTRIX LLC (US) | 2016-10-06 | — | — | US | disclosed |
| US-9216975-B2 | TRPV1 vanilloid receptor antagonists with a bicyclic portion | Serentrix, LLC. (US) | 2015-12-22 | — | — | US | disclosed |
| CN-102858742-B | Trpv1 vanilloid receptor antagonists with a bicyclic portion | PHARMESTE SRL | 2015-05-27 | — | — | CN | disclosed |
| US-20130079339-A1 | TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION | PHARMESTE S.R.L. (IT) | 2013-03-28 | — | — | US | disclosed |
| EP-2552888-A1 | \"TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION\ | Pharmeste S.r.l. (IT) | 2013-02-06 | — | — | EP | disclosed |
| CN-102858742-A | Trpv1 vanilloid receptor antagonists with a bicyclic portion | PHARMESTE SRL | 2013-01-02 | — | — | CN | disclosed |
| EP-2377850-A1 | TRPV1 vanilloid receptor antagonists with a bicyclic portion | Pharmeste S.r.l. (IT) | 2011-10-19 | — | — | EP | disclosed |
| WO-2011120604-A1 | \"TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION\ | PHARMESTE S.R.L. (IT) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152252-A1 | TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion | TRPV1, TRPV5, TRPV3 | ALDH1A1 2275/4885CYP1A2 2875/4885CYP2C9 2904/4885 |
| US-10233177-B2 | TRPV1 vanilloid receptor antagonists with a bicyclic portion | TRPV1, TRPV5, TRPV3 | ALDH1A1 2275/4885CYP1A2 2875/4885CYP2C9 2904/4885 |
| US-20160289199-A1 | TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion | TRPV1, TRPV5, TRPV3 | ALDH1A1 2275/4885CYP1A2 2875/4885CYP2C9 2904/4885 |
| US-20130079339-A1 | TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION | TRPV1, TRPV5, TRPV3 | ALDH1A1 2275/4885CYP1A2 2875/4885CYP2C9 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.